John McDermott

John McDermott serves as the CEO of Vascular Therapies since 2019 and has held a board member position at Paragonix Technologies, Inc. and Auxetics since 2020 and 2022, respectively. From 2008 to 2018, John was the CEO and a member of the Board of Directors at Endologix. Prior roles include board membership at Entellus Medical (2014-2016) and Angiotech Pharmaceuticals (1998-2001), as well as multiple leadership roles at CR Bard from 1996 to 2007, including President of Bard Peripheral Vascular. John also served as Vice President and Chief Operating Officer at IMPRA, INC. in 1995-1996 before its acquisition by CR Bard, and held the role of Chief Financial Officer at IMPRA, Inc. from 1990 to 1995. Academically, John McDermott holds an MBA from Western International University and a BS in Finance from Arizona State University.